SSX5抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P05364(SSX5 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05364(SSX5 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SSX5 antibody is designed to target the SSX5 protein, a member of the SSX (synovial sarcoma X breakpoint) family of cancer/testis (CT) antigens. SSX proteins are normally expressed in germline cells, particularly in the testes, but are aberrantly reactivated in various cancers, including melanoma, sarcoma, and carcinomas. This restricted expression pattern makes SSX proteins, including SSX5. attractive targets for cancer immunotherapy and diagnostic applications.

SSX5 is involved in transcriptional regulation and chromatin remodeling, often through interactions with polycomb-group proteins. Its oncogenic potential is linked to its ability to disrupt epigenetic regulation, promoting tumor progression and immune evasion. Antibodies against SSX5 are primarily utilized in research to study its expression patterns, subcellular localization, and functional roles in cancer biology. They are employed in techniques such as immunohistochemistry (IHC), Western blotting, and immunofluorescence to detect SSX5 in tumor samples or cell lines.

Clinically, SSX5 antibodies may aid in cancer diagnosis, prognosis, or monitoring treatment responses. Additionally, they hold potential in developing targeted therapies, such as CAR-T cells or antibody-drug conjugates, by identifying SSX5-expressing tumors. However, challenges remain, including cross-reactivity with other SSX family members and variability in tumor antigen expression. Ongoing research aims to refine SSX5-specific antibodies and explore their therapeutic utility in precision oncology.